Illumina Enters into Collaboration With Cancer Research UK
Posted on: Wednesday, 12 April 2006, 21:00 CDT
Illumina is to conduct genotyping of prostate cancer patients and controls in order to help researchers funded by Cancer Research UK to understand the genetic causes of the disease.
From the work, it is hoped that it will be possible in the future to design and validate biomarkers associated with prostate cancer susceptibility and disease progression, as well as to facilitate development of improved therapeutic approaches.
Under the terms of the agreement, valued at nearly $7 million, Illumina's service group will conduct whole-genome genotyping for at least 4,000 well-classified prostate patients and controls.
A second phase will involve development of a custom, 12-sample BeadChip that will enable analysis of 24,000 SNPs (single nucleotide polymorphisms) per sample and be used to genotype at least 8,000 samples.
Illumina is also collaborating with Cancer Research UK on genotyping colorectal cancer samples and controls.
"My colleagues and I believe firmly that this type of research will yield dramatically improved understanding of prostate cancer and thereby outcomes for cancer patients," said Harpal Kumar, COO of Cancer Research UK.
Source: Datamonitor
Related Articles
- Thomson Reuters and the National Foundation for Cancer Research Provide Online Help for Cancer Patients
- Workout Fundraising Event to Support Prostate Cancer Research
- Safeway Kicks Off Month of Events and Fundraising for Prostate Cancer Research and Awareness
- Cancer Researchers at Manhattan-Based St. Vincent's Comprehensive Cancer Center Discover Genes That Can Determine How Patients Respond to Pre-Leukemia Drug
- Illumina Signs Fourth Genotyping Service Agreement With Leading UK-Based Cancer Research Group
- Mutual Fund Industry Raises 0ver $350,000 For Cancer Research
- CN Donates $250,000 to the Atlantic Cancer Research Institute's Discoveries Campaign to Fight Against Cancer
- The Leukemia & Lymphoma Society's On Target For A Cure Clay Tournament Raises $280,000 for Cancer Research and Patient Aid
- The University of Cambridge, Cancer Research Technology, Cancer Research UK and Perlegen Sciences Collaborate to Analyze Thousands of DNA Samples From Breast Cancer Patients
 |
 |
User Comments (0)
RSS Feeds